TABLE 1. Demographic and epidemiologic characteristics of adults with mpox, by age group (N = 29,984) — United States, May 10, 2022–May 17, 2023.
| Characteristic and clinical outcome | Age group, no. (column %)* |
p-value† | |
|---|---|---|---|
| 18–50 yrs n = 27,075 | >50 yrs n = 2,909 | ||
|
Gender identity
| |||
| Cisgender men |
25,681 (95.2) |
2,794 (96.3) |
<0.001 |
| Cisgender women |
809 (3.0) |
88 (3.0) |
|
| Transgender men |
55 (0.2) |
0 (—) |
|
| Transgender women |
220 (0.8) |
9 (0.3) |
|
| Other gender identity |
225 (0.8) |
11 (0.4) |
|
| Missing |
85 |
7 |
|
|
Race and ethnicity§
| |||
| Black or African American |
8,733 (34.2) |
561 (20.5) |
<0.001 |
| White |
7,085 (27.8) |
1,297 (47.3) |
|
| Hispanic or Latino |
7,878 (30.9) |
758 (27.7) |
|
| Other |
1,684 (6.6) |
120 (4.4) |
|
| Multiracial |
134 (0.5) |
4 (0.1) |
|
| Missing |
1,561 |
169 |
|
|
Any sexual contact during the 3 wks preceding illness onset
| |||
| Yes |
15,495 (78.6) |
1,618 (77.0) |
0.083 |
| No |
4,216 (21.4) |
484 (23.0) |
|
| Missing |
7,364 |
807 |
|
|
Sexual partner among cisgender men¶
| |||
| Cisgender men only |
12,561 (93.5) |
1,393 (94.8) |
0.201 |
| Cisgender men and other genders |
419 (3.1) |
32 (2.2) |
|
| Exclude cisgender men |
454 (3.4) |
45 (3.1) |
|
| Missing |
12,247 |
1,324 |
|
|
HIV status
| |||
| HIV positive |
4,798 (55.4) |
552 (66.2) |
<0.001 |
| HIV negative |
3,860 (44.6) |
282 (33.8) |
|
| Unknown HIV status or missing |
18,417 |
2,075 |
|
|
Immunocompromising condition**
| |||
| Yes |
1,308 (11.1) |
185 (15.0) |
<0.001 |
| No |
10,466 (88.9) |
1,045 (85.0) |
|
| Missing |
15,301 |
1,679 |
|
|
Received ≥1 dose of JYNNEOS vaccine
| |||
| Yes |
2,481 (21.3) |
282 (27.6) |
<0.001 |
| No |
9,177 (78.7) |
738 (72.4) |
|
| Missing |
15,417 |
1,889 |
|
|
Rash††
| |||
| Yes |
6,867 (96.8) |
563 (96.6) |
0.72 |
| No |
224 (3.2) |
20 (3.4) |
|
| Missing |
2,086 |
155 |
|
|
Pruritus††
| |||
| Yes |
2,972 (58.7) |
221 (59.4) |
0.78 |
| No |
2,092 (41.3) |
151 (40.6) |
|
| Missing |
4,113 |
366 |
|
|
Rectal symptoms††,§§ or abdominal pain
| |||
| Yes |
2,719 (50.3) |
134 (37.3) |
<0.001 |
| No |
2,683 (49.7) |
225 (62.7) |
|
| Missing |
3,775 |
379 |
|
|
Constitutional symptoms††,¶¶
| |||
| Yes |
6,103 (91.2) |
424 (85.0) |
<0.001 |
| No |
586 (8.8) |
75 (15.0) |
|
| Missing |
2,488 |
239 |
|
|
Hospitalization††
| |||
| Yes |
657 (7.5) |
58 (8.3) |
0.459 |
| No |
8,110 (92.5) |
644 (91.7) |
|
| Missing |
410 |
36 |
|
|
Death††
| |||
| Yes |
12 (0.2) |
3 (0.6) |
0.069 |
| No |
6,488 (99.8) |
532 (99.4) |
|
| Missing | 2,677 | 203 | |
* Percentages were calculated using nonmissing data.
† Pearson’s chi-square or Fisher’s exact test.
§ Persons of Hispanic or Latino (Hispanic) origin might be of any race but are categorized as Hispanic; all racial groups are non-Hispanic.
¶ Only among cisgender men aged 18–40 years (25,681) and >50 years (2,794).
** Excluding HIV infection and AIDS.
†† Clinical outcomes were compared by age group after excluding adults who received JYNNEOS vaccine (2,763).
§§ Includes rectal pain/bleeding, pus in the stool, proctitis, or tenesmus.
¶¶ Includes fever, headache, malaise, myalgia, chills, or lymphadenopathy.